PTC Therapeutics Reports Q2 2026 Results; Appoints New Director

What Happened

• PTC Therapeutics, Inc. (PTCT) announced financial results for the quarter ended June 30, 2026 and furnished a related press release as Exhibit 99.1 to its Form 8‑K filed July 30, 2026. The company also scheduled a conference call for July 30, 2026 at 4:30 p.m. ET to review the quarter and corporate updates.
• On July 28, 2026 the company appointed Hege Sollie‑Zetlmayer to its board as a Class III director (term expiring at the 2028 annual meeting). Ms. Sollie‑Zetlmayer, who served in senior HR roles at PTC from 2018 until her retirement in June 2026, will receive standard outside director cash and equity compensation.

Key Details

• Conference call: July 30, 2026 at 4:30 p.m. ET to discuss quarterly results and updates; access details are in the press release (Exhibit 99.1).
• Director pay: non‑employee directors receive a $50,000 base annual retainer; the company will reimburse reasonable travel/meeting expenses for Ms. Sollie‑Zetlmayer.
• Equity awards to new director (per the 2013 LTIP): initial grant of 3,475 stock options (vest monthly over 36 months starting one month after grant) and 4,000 restricted stock units (vest in three equal annual installments beginning July 28, 2027). Pro‑rated 2026 annual grant: 1,738 options (vest in six equal monthly installments from Aug 2, 2026) and 2,000 RSUs (vest Jan 2, 2027).
• Corporate governance note: there are no arrangements or related‑party transactions requiring additional disclosure under Item 404; information in the Form 8‑K (including the press release) is furnished, not “filed,” for certain legal purposes.

Why It Matters

• The filing signals PTC has released its Q2 2026 quarterly results and is providing an earnings call for investors to hear management commentary and ask questions. Investors should review the press release (Exhibit 99.1) for the detailed financials and metrics.
• The board appointment adds an executive with extensive HR and global talent experience at PTC, which may be relevant for governance and workforce strategy. The disclosed equity awards create potential share dilution over time and are typical for non‑employee director compensation.